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Stroke and Atrial Fibrillation Ablation. Introduction: Factors associated with cerebrovascular
events (CVEs) after radiofrequency catheter ablation (RFA) of atrial fibrillation (AF) have not been well
defined in elderly patients (≥65 years). The purpose of this study was to determine the prevalence and
predictors of CVEs after RFA in patients with AF ≥65 years old, in comparison to patients <65 years, and
with or without AF.
Methods and Results: This study included 508 consecutive patients ≥65 years old (mean age: 70 ± 4
years), who underwent RFA for paroxysmal (297) or persistent (211) AF. A stratified group of 508 patients
<65 years old who underwent RFA for AF served as a control group. All patients were anticoag-
ulated with warfarin for ≥3 months after RFA. A perioperative CVE (≤4 weeks after RFA) oc-
curred in 0.8% and 1% of patients ≥65 and <65 years old, respectively (P = 1). Among the
patients ≥65 years old who remained in sinus rhythm after RFA, warfarin was discontinued in 60%
and 56% of the patients with a CHADS2 score of 0 and ≥1, respectively. Paroxysmal AF, no his-
tory of CVE, and successful RFA were independent predictors of discontinuing warfarin. During a
mean follow-up of 3 ± 2 years, a late CVE (>4 weeks after the RFA) occurred in 15 of 508 (3%) of
patients ≥65 years old (1% per year) and in 5 of 508 (1%) patients<65 years old (0.3% per year, P = 0.03).
Among patients ≥65 years old, age >75 years old (OR = 4.9, ±95% CI: 3.3–148.5, P = 0.001) was the only
independent predictor of a CVE. Among patients<65 years old, body mass index was the only independent
predictor of a late CVE (OR = 1.2, ±95% CI: 1.03–1.33, P = 0.02).
Conclusions: The risk of a periprocedural CVE after RFA of AF is similar among patients ≥65 and <65
years old. Late CVEs after RFA are more prevalent in older than younger patients with AF, and age >75
years old is the only independent predictor of late CVEs regardless of the rhythm, anticoagulation status,
or the CHADS2 score (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus and prior
Stroke or transient ischemic attack). (J Cardiovasc Electrophysiol, Vol. 23, pp. 36-43, January 2012)
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Atrial fibrillation (AF) is associated with a 5- to 6-fold in-
crease in the risk of cerebrovascular events (CVE) and is the
leading cause of ischemic strokes.1 Although maintenance
of sinus rhythm would be expected to restore atrial contrac-
tile function and eliminate the propensity for endovascular
thrombus formation because of stasis, it has been suggested
that patients with AF have intrinsic thrombophilia indepen-
dent of the rhythm and that AF is a surrogate comorbidity of
a systemic disease.2-4
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Anticoagulation with warfarin can have a profound effect
on quality of life and is associated with a risk of major bleed-
ing. Therefore, discontinuation of systemic anticoagulation
after successful radiofrequency catheter ablation (RFA) of
AF bears substantial significance. A prior study suggested
that anticoagulation safely can be discontinued after RFA
in patients ≤65 years old.5 However, it is not clear whether
systemic anticoagulation also can be safely discontinued in
older patients, who are at higher risk for CVEs.6 The purpose
of this study was to determine the prevalence and predictors
of CVEs after RFA of AF in patients ≥65 years old in com-
parison to patients <65 years old.
Methods
Study Subjects
The study included 508 consecutive patients who were ≥
65 years old and underwent RFA to eliminate paroxysmal
(297, 58%) or persistent AF (211, 42%) between 2001 and
2009. The mean age was 70 ± 3 years (range: 65–83 years).
There were 323 men and 185 women. AF was first diag-
nosed 6 ± 6 years before the presentation. The mean left
atrial diameter was 44 ± 7 mm and the mean left ventricular
ejection fraction was 0.56 ± 0.08. Among the 508 patients,
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TABLE 1
Clinical Characteristics
Patients Patients
≥65 years <65 years
old (n = 508) old (n = 508) P Value
Age (years) 70 ± 3 53 ± 9 –
Paroxysmal AF/persistent AF 297/211 316/192 0.25
Gender (male/female) 323/185 405/103 <0.001
Duration of AF (years) 6.4 ± 6.2 5.5 ± 5.5 0.014
Body mass index (kg/m2) 29.1 ± 5.7 31.4 ± 6.1 <0.001
Left atrial diameter (mm) 43.9 ± 6.6 42.9 ± 6.7 0.017
Left ventricular ejection fraction 0.56 ± 0.08 0.56 ± 0.09 0.85
Coronary artery disease (%) 116 (23) 40 (8) <0.001
Dilated cardiomyopathy (%) 10 (2) 23 (4) 0.021
Prior CVE (%) 44 (9) 20 (4) 0.003
Mean CHADS2 score 1.1 ± 0.9 0.7 ± 0.8 <0.001
CHADS2 score 0 131 (26) 234 (46) <0.001
CHADS2 score 1 253 (50) 218 (43) 0.03
CHADS2 score 2 86 (17) 40 (8) <0.001
CHADS2 score 3 28 (6) 16 (3) 0.09
CHADS2 score 4 10 (2) 0 (0) 0.002
Continuous variables are expressed as mean ± SD. Percent values are
shown in parentheses.
AF = atrial fibrillation; CVE = cerebrovascular event.
the CHADS2 score was 0 in 131 (26%), 1 in 253 (50%), and
≥2 in 124 patients (24%; Table 1).
A stratified control group consisted of 508 patients who
were <65 years old and underwent RFA to eliminate parox-
ysmal (316) or persistent AF (192) within the same period.
To account for temporal changes in the ablation technique
and duration of follow-up over 9 years, control subjects were
chosen as the same number of consecutive patients who un-
derwent RFA in the same monthly intervals as the study
subjects during each year of the study. The mean age of the
patients in the control group was 53 ± 9 years (range: 20–64
years). The mean CHADS2 score was 1.1 ± 0.9 (range: 0–4)
and 0.7 ± 0.8 (range: 0–3) among patients who were ≥65
and <65 years old, respectively (P < 0.001; Table 1).
Study Protocol
The study protocol was approved by the institutional re-
view board. The purpose of this retrospective analysis was to
determine the prevalence and predictors of CVEs after RFA
in patients with AF who were ≥65 years old in relation to
the anticoagulation status. A stratified group of patients with
AF who were <65 years old and who underwent RFA during
the same period served as a control group.
To assess the role of RFA in preventing CVEs, 2 hypo-
thetical cohorts were formed based on the Framingham study
to serve as additional control groups: (1) otherwise healthy
subjects who are ≥65 years old with no history of AF7 and
(2) patients ≥65 years old who did not undergo RFA to
eliminate AF.1
Radiofrequency Catheter Ablation
All patients underwent left atrial circumferential abla-
tion or antral pulmonary vein isolation. Ablation of complex
fractionated atrial electrograms and linear ablation was per-
formed at the discretion of the operator.8,9
Anticoagulation Regimen
A transesophageal echocardiogram was obtained in pa-
tients with persistent AF and in patients with a history of
CVE or left atrial appendage thrombus before the procedure.
During this study period, warfarin was discontinued 3–5 days
before the procedure in all patients and low-molecular-weight
heparin (enoxaparin) was administered until the procedure.
During RFA, systemic anticoagulation was achieved with
a bolus of intravenous heparin (100 U/kg) immediately after
the transseptal puncture and a continuous infusion of heparin
(∼1,000 U/hour) was initiated with intermittent boluses as
necessary to maintain the activated clotting time (ACT) at
300–350 seconds. Heparin was discontinued at the conclu-
sion of left atrial ablation, and sheaths were removed once the
ACT was <180 seconds. Anticoagulation was not reversed
unless there was a hemorrhagic emergency.
Three hours after sheath removal, heparin infusion was
started at a rate of 1,000 U/hour and was maintained
overnight. Warfarin was restarted at the regular maintenance
dose on the day of the procedure. Enoxaparin was admin-
istrated at 0.5 mg/kg bid until the international normalized
ratio (INR) was ≥2.
After confirming maintenance of sinus rhythm with an
autotriggered event monitor ≥3 months after RFA, aspirin,
81–325 mg/day was substituted for warfarin unless there was
another indication to continue anticoagulation or a history of
CVE. In some cases, the referring physician decided to have
the patient continue taking warfarin despite the recommen-
dation to substitute warfarin.
Clinical Follow-Up
Patients were seen in an outpatient clinic 3 months af-
ter the RFA, and every 3–6 months for up to 2 years un-
less they had recurrent symptoms or atrial arrhythmias. Pa-
tients then were periodically monitored and contacted by a
nurse. Patients also were instructed to call whenever they
had symptoms and were provided with an event monitor.
The last follow-up was performed in 2010, in all patients.
The mean duration of follow-up was 34 ± 24 months and
34 ± 25 months in patients ≥65 and <65 years old, respec-
tively. A successful RFA was defined as the absence of atrial
tachyarrhythmias >60 seconds in duration after a 3-month
blanking period.
Statistical Analysis
Continuous variables are expressed as mean ± standard
deviation and were compared with Student’s t-test or Mann–
Whitney U-test as appropriate. Categorical variables were
compared by χ2analysis or Fisher’s exact test, as appro-
priate.2 Kaplan–Meier analysis was performed to determine
cumulative proportion of patients who remained free from
CVEs in each group. Multivariate Cox regression analysis
was utilized to identify the predictors of CVEs. A P < 0.05
indicated statistical significance.
Results
CVEs Before RFA
A CVE was reported in 44 of 508 patients (9%) who
were ≥65 years old and 20 of 508 patients (4%) who
were <65 years old before the RFA procedure (P = 0.003).
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The prevalence of CVEs before RFA was similar among
patients who had paroxysmal or persistent AF, both in
patients ≥65 years old (27/297 [9%] vs 17/211 [8%],
P = 0.68), and in patients <65 years old (12/316 [4%] vs
8/192 [4%], P = 0.84), respectively.
Periprocedural CVEs
A periprocedural CVE (≤4 weeks after RFA) occurred in
4 of 508 (0.8%) patients ≥65 years old and in 5 of 508 (1%)
patients <65 years old at a mean of 6 ± 5 days after RFA
(P = 1). At the time of the CVE, patients were in AF or atrial
flutter, except for 1 patient who was in sinus rhythm.
In patients ≥65 years old, 1 patient had a TIA (transient
ischemic attack, day 4), 2 patients had a stroke (day 0 and
8), and 1 patient had an intracranial hemorrhage (day 12).
The patient with a TIA had transient slurring of speech.
Both patients who suffered from a stroke complained of mild
hemiparesis and facial droop, which completely resolved by
10 and 12 months, respectively. A spontaneous intracerebral
bleed was discovered on day 12, in a patient who presented
with headache. The international normalized ratio (INR) was
>3 and the patient recovered after surgical drainage.
In patients <65 years old, each of the 5 periprocedural
CVEs occurred ≤2 weeks after RFA and was a TIA. Transient
aphasia was noticed in 1 patient and visual disturbances in
the 4 remaining patients. All patients had a subtherapeutic
INR at the time of the CVE; however, 3 of 5 patients were
receiving enoxaparin.
Among the patients ≥65 years old, 4 of 4 (100%) and 373
of 504 (74%) who did and did not experience a periproce-
dural CVE, had ≥1 CHADS2 risk factor (P = 0.2), whereas
in patients <65 years old, 2 of 5 (40%) and 272 of 503
(54%) who did and did not experience a periprocedural CVE
had ≥1 CHADS2 risk factor for stroke (P = 0.5).
Rhythm Status After RFA
A total of 784 and 787 procedures were performed in
the 508 patients ≥65 years old and in the 508 patients
<65 years old, respectively. At 28 ± 23 months after the
most recent RFA, among the patients ≥65 years old, 226
of 297 patients (76%) with paroxysmal AF and 126 of 211
patients (60%) with persistent AF were in sinus rhythm,
free from atrial tachyarrhythmias. In patients <65 years
old, 253 of 316 patients (80%) with paroxysmal AF and
121 of 192 patients (63%) with persistent AF were in sinus
rhythm.
Discontinuation of Warfarin After RFA
Warfarin was less likely to be discontinued after RFA in
patients ≥65 years old (48%) than in patients <65 years
old (63%, P < 0.001). Warfarin was discontinued later after
the RFA in patients ≥65 years old, 8 ± 9 months, than in
patients <65 years old, 5 ± 4 months (P < 0.001).
In patients who remained in sinus rhythm after RFA and
had a CHADS2 score of 0, warfarin was discontinued in 53 of
89 (60%) and in 121 of 172 (70%) in patients ≥65 and <65
years old, respectively (P = 0.10). Among the patients who
remained in sinus rhythm after RFA and had a CHADS2
score ≥1, warfarin was discontinued in 149 of 264 (56%)
and in 148 of 201 (74%) in patients ≥65 and <65 years old,
respectively (P = 0.002).
TABLE 2
Multivariate Analysis of Predictors of Discontinuation of Warfarin After
RFA
Odds Ratio (±95%
Confidence Interval) P Value
Patients ≥65 years old
Paroxysmal AF 2.0 (1.3–2.9) 0.0006
No history of CVE 2.3 (1.2–4.4) 0.0184
Successful ablation 3.6 (2.4–5.6) <0.0001
Patients <65 years old
Paroxysmal AF 2.6 (1.7–3.9) <0.0001
No history of CVE 13.6 (3.8–49.4) <0.0001
Successful ablation 4.1 (2.7–6.4) <0.0001
All patients (n = 1016)
Paroxysmal AF 2.6 (1.9–3.3) <0.0001
Hypertension 0.8 (0.6–0.99) 0.04
No history of CVE 3.2 (1.7–5.8) 0.0002
Successful ablation 4.8 (3.6–6.3) <0.0001
AF = atrial fibrillation; CVE = cerebrovascular event; RFA= radiofrequency
catheter ablation.
Predictors of Discontinuing Warfarin After RFA
In patients ≥65 years old, among the clinical variables of
age ≥75 years old, gender, type of AF, hypertension, dia-
betes mellitus, congestive heart failure, prior CVE, duration
of AF, left atrial size, and maintenance of sinus rhythm after
the RFA, paroxysmal AF before RFA (OR = 2.0; ±95% CI:
1.3–2.9; P < 0.0006), no history of CVE (OR = 2.3; ±95%
CI: 1.2–4.4; P = 0.018), and sinus rhythm after the RFA
(OR = 3.6; ±95% CI; 2.4–5.6; P < 0.0001) were indepen-
dently associated with discontinuation of warfarin after the
RFA (Table 2).
In patients <65 years old, paroxysmal AF before RFA
(OR = 2.6; ±95% CI: 1.7–3.9; P < 0.0001), no history
of CVE (OR = 13.6; ±95% CI: 3.8–49.4; P < 0.0001),
and sinus rhythm after RFA (OR = 4.1; ±95% CI: 2.7–6.4;
P < 0.0001) were independent predictors of discontinuation
of warfarin after the RFA (Table 2).
Late CVEs After RFA
During a mean follow-up of 34 ± 24 months, a late
CVE (>4 weeks after RFA) occurred in 15 of 508 patients
(3.0%) ≥65 years old (1% per year), and in 5 of 508 pa-
tients (1%) <65 years old (0.3% per year) after 1.5 ± 0.8
procedures, (P = 0.03). CVEs included a TIA in 1, a stroke
in 11, an intracerebral hemorrhage in 3 patients ≥65 years
old, and a TIA in each of the 5 patients <65 years old
(P = 0.1 for TIA, P < 0.001 for stroke, and P = 0.1 for
intracerebral hemorrhage). At the time of the CVE, AF was
documented in 11 of 15 (73%) and 2 of 5 (40%) patients ≥65
and <65 years old, respectively (P = 0.3). During follow-
up, 2 patients died: 1 from an intracerebral hemorrhage and
the other from a stroke, 51 days and 7 years after RFA,
respectively. In both patients the INR was subtherapeutic
(1.2–1.7).
Discontinuation of Warfarin After RFA and CVEs
Among patients ≥65 years old, a CVE occurred in 7 of
242 (2.9%) and in 8 of 266 (3.0%) in whom warfarin was
and was not discontinued after RFA, respectively (P = 1).
Among patients <65 years old, a CVE occurred in 3 of 319
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(0.9%) and in 2 of 189 (1.1%) in whom warfarin was and
was not discontinued after the RFA, respectively (P = 1).
CHADS2 Score and CVEs After RFA
The mean CHADS2 score was 1.2 ± 1.1 and 1.1 ± 0.9
in patients ≥65 years old who did and did not have a CVE
(P = 0.9) and 0.9 ± 1.0 and 0.7 ± 0.8 in patients <65 years
old who did and did not have a CVE after the RFA (P = 0.5).
Among patients ≥65 years old, 13 of 15 (87%) and 366
of 493 patients (74%) who did and did not experience a
late CVE had a CHADS2 score ≥1 (P = 0.4), whereas in
patients <65 years old, 4 of 5 (80%) and 270 of 503 patients
(54%) who did and did not experience a late CVE had a
CHADS2 score ≥1 (P = 0.2).
CHADS2 Score, Discontinuation of Warfarin and CVE
Among patients ≥65 years old, warfarin was discontinued
in 199 of 377 patients (53%) who had a CHADS2 score ≥1
and in 63 of 131 patients (48%) who had a CHADS2 score
of 0 (P = 0.4). A CVE occurred in 13 of 377 patients (3%)
who had a CHADS2 score ≥1 and in 2 of 131 patients (2%)
who had a CHADS2 score of 0 (P = 0.4). After a successful
procedure, the risk of CVE was similar between patients who
had a CHADS2 score ≥1 and were on warfarin (4/115, 3%)
and patients who had a CHADS2 score of 0 and were off
warfarin (0/53, P = 0.3).
Predictors of CVEs After RFA
In patients ≥65 years old, among the clinical variables
of age, gender, AF type, left atrial size, body mass index
(BMI), AF duration, diabetes mellitus, hypertension, coro-
nary artery disease, dilated cardiomyopathy, left ventricu-
lar ejection fraction, CHADS2 score, prior CVE, success-
ful ablation, and discontinuation of warfarin therapy, the
only independent predictor of CVEs was age >75 years old
(OR = 4.9; ±95% CI: 1.7–14.5; P = 0.004 for all CVEs and
OR = 7.0; ±95% CI: 2.3–21.6; P = 0.0008 for late CVEs;
Table 3). Age was also an independent predictor of CVEs
when analyzed as a continuous variable (OR = 7.9; ±95%
CI: 2.5–25.2; P = 0.0004).
Among patients ≥65 years old who maintained sinus
rhythm after the RFA and who had discontinued warfarin
(n = 202), age >75 years old was also the only predictor
of CVEs (OR = 21.2; ±95% CI: 3.3–138.5; P = 0.0014;
Table 4).
In patients <65 years old, there were no independent pre-
dictors of CVEs during or after the RFA. However, BMI
was identified as an independent predictor of CVEs that
occurred >4 weeks after the RFA (OR = 1.2; ±95% CI:
1.03–1.33; P = 0.015; Table 3). Anticoagulation status and
CHADS2 score were not predictive of a CVE in any model
(Table 3).
Intracranial Hemorrhage
An intracranial hemorrhage occurred in 4 of 1016 patients
(0.4%) and consisted of a subdural hematoma after a fall
(INR = 1.6) that resolved after discontinuation of warfarin,
a cerebellar hemorrhage (INR = 3.7) with recovery after
reversal of anticoagulation, an intracerebral bleed (INR > 3)
that resolved after neurosurgery, and an intracerebral bleed
TABLE 3
Multivariate Analysis of Predictors of CVEs After RFA of AF
Odds Ratio (±95%
Confidence Interval) P Value
Patients ≥65 years old
All CVEs
Age >75 years old 4.9 (1.7–14.5) 0.004
Late (>4 weeks) CVEs
Age >75 years old 7.0 (2.3–21.6) 0.0008
Patients <65 years old
All CVEs No predictors
Late CVEs
BMI 1.2 (1.03–1.33) 0.015
All Patients
All CVEs
Age >75 years old 6.0 (2.1–17.1) 0.0007
Diabetes mellitus 2.5 (1.02–6.2) 0.044
Late CVEs
Age >75 years old 9.7 (3.3–28.4) <0.0001
AF = atrial fibrillation; BMI = body mass index; CVE = cerebrovascular
event; RFA= radiofrequency catheter ablation.
(INR = 1.7) that was fatal. All patients were ≥65 years old
and were in AF (n = 3) or in atrial flutter (n = 1).
Risk of CVE
During a mean follow-up of 3 ± 2 years old, the cumula-
tive proportion of patients who remained free from any CVE
(periprocedural or late CVE) after RFA was 96.3% in patients
≥65 years old and 98% in patients <65 years old, respec-
tively (P = 0.095; Fig. 1). The proportion of patients who
remained free from a late CVE was 97% in patients ≥65
years old and 99% in patients <65 years old, respectively
(P = 0.024; Fig. 2).
Among patients who had a successful outcome after RFA
of AF and who were no longer receiving warfarin, 198 of
202 (98%) patients ≥65 years old (0.7% risk of CVE per
year) and 266 of 269 (98.8%), patients <65 years old (0.4%
risk of CVE per year) were free from late CVEs (P = 0.70;
Fig. 3).
The expected cumulative freedom from a CVE in a hy-
pothetical cohort of human subjects ≥65 years old was
98.2% among those with no history of AF and 95.9% among
those with AF who did not undergone RFA of the AF
(Fig. 3).
TABLE 4
Multivariate Analysis of Predictors of Late CVEs in Patients Who
Discontinued Warfarin After Successful RFA of AF
Odds Ratio (±95%
Confidence Interval) P Value
Patients ≥65 years old (n = 202)
Age >75 years old 21.2 (3.3–138.5) 0.0014
Patients <65 years old (n = 269)
CHADS2 score ≥1 8.8 (7.0–13.0) 0.054
All patients (n = 471) No predictors
CVE = cerebrovascular event.
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Figure 1. Freedom from any CVE after RFA of AF. On an intention-to-treat analysis, during a mean follow-up of 3 ± 2 years, cumulative proportion of
patients ≥65 years old (red dotted line) who remained free from any CVE after RFA of AF was similar to patients <65 years old (blue line, P = 0.095,
log-rank test).
Discussion
Main Findings
The main findings of this study are: (1) a periprocedural
CVE may occur in ∼1% of patients after RFA of AF, usually
within 2 weeks of the procedure and has a similar preva-
Figure 2. Freedom from late CVEs after RFA of AF. On an intention-to-treat analysis, patients ≥65 years old (red dotted line) were more likely to have late
CVEs (>4 weeks) after RFA of AF than patients <65 years old (blue line, P = 0.024, log-rank test).
lence in patients ≥65 and <65 years old; (2) warfarin is
discontinued sooner and in a higher proportion of patients <
65 years old than ≥65 years old after RFA, despite similar
efficacy; (3) warfarin is more likely to be discontinued after
RFA in patients with paroxysmal AF, no history of a CVE,
and freedom from AF regardless of age; (4) the incidence
Guiot et al. Stroke and Atrial Fibrillation Ablation 41
of a late CVE after RFA is higher in patients ≥65 years old
(1% per year) than in patients <65 years old (0.3% per year);
(5) in patients ≥65 years old, age >75 years old is the only
predictor of CVEs after RFA, whereas in patients <65 years
old, a higher BMI is associated with late CVEs; (6) warfarin
therapy and CHADS2 score are not predictive of CVEs after
RFA of AF, regardless of age; and (7) among patients ≥65
years old, at 3 years after RFA, cumulative freedom from any
CVE is 98% in patients who discontinue warfarin after suc-
cessful RFA of AF compared to 96% in patients with AF who
do not undergo RFA, and 98% in otherwise healthy subjects
with no history of AF.
Periprocedural CVEs
Periprocedural CVEs occurred in ∼1% of patients dur-
ing and early after RFA regardless of age. The technique of
RFA, ablation technology, and the periprocedural anticoag-
ulation regimen rather than preexisting conditions are likely
to play an important role in periprocedural CVEs. Therefore,
age by itself should not be a concern as far as the risk of
periprocedural CVEs is considered.
Periprocedural CVEs were most prevalent early after
RFA, a period when anticoagulation may have been subther-
apeutic because of bridging with LMWH during reinitiation
of warfarin therapy.5 However, as the recently proposed ap-
proach of performing RFA without discontinuing warfarin is
more widely adopted and the ablation technologies are more
refined, the prevalence of periprocedural CVEs is likely to
decrease.10
Figure 3. Freedom from late CVEs after discontinuation of warfarin. At 33 months, freedom from late CVEs is shown in patients: (1) with AF and ≥65 years
old after successful RFA and discontinuing warfarin (green dotted line); (2) with AF and <65 years old after successful RFA and discontinuing warfarin
(black line); (3) with AF and ≥ 65 years old who had not undergone RFA for AF (red dotted line); and (4) without AF and ≥65 years old (blue line). SR =
sinus rhythm.
Late CVEs
A CVE was reported in 0.5–7% of patients after RFA of
AF in prior studies.5,11,12 However, the effect of age on the
risk of CVEs has not been systematically analyzed. In this
study, the risk of a CVE was significantly higher, 1% per year,
in patients ≥65 years old than in patients <65 years old, 0.3%
per year, after RFA of AF. Similar to the findings of a prior
study, the incidence of late CVEs was low (0.2% per year)
in patients <65 years old who remained in sinus rhythm and
discontinued warfarin after successful RFA.5 The incidence
of a late CVE was 0.7% per year in patients ≥65 years old
who discontinued warfarin after successful ablation in this
study and appears to be lower than the incidence of 2.3% per
year of CVEs reported in a recent analysis of stroke risk in
patients with AF.13
The only independent predictor of CVEs in patients ≥65
years old was age >75 years old regardless of the rhythm, an-
ticoagulation status, or the CHADS2 score. There are several
possible explanations for this observation: (1) age-related co-
morbidities such as hypertension, vascular disease, and senile
degenerative changes such that elimination of AF does not
eliminate the risk of CVEs; (2) asymptomatic recurrences
of AF that were not detected during follow-up. However,
asymptomatic recurrences of AF are not known to be more
prevalent in older than in younger patients; (3) the antico-
agulant effects of warfarin may not have been sufficient to
completely eliminate thrombus formation in all patients with
AF. Furthermore, warfarin is associated with a risk of in-
tracranial bleeding, which may negate the beneficial effects
particularly in low- and intermediate-risk patients; and (4)
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RFA has been shown to result in a ≥30% decrease in left
atrial contractile and transport function. Older patients may
have a greater degree of preexisting left atrial fibrosis, such
that further declines in left atrial contractile function because
of RFA may lead to a clinically significant compromise in left
atrial transport function. It should be noted that age remains
as an independent predictor of late CVEs when analyzed as
a continuous variable. Because aging is a dynamic process,
it may be more helpful to consider age as a continuum in
assessing the risk of CVEs rather than as a discrete threshold
value in risk prediction models.
Consistent with the prior reports on association between
high BMI and risk of stroke,14-16 BMI was indentified as an
independent predictor of late CVEs in patients <65 years
old after RFA of AF in this study. The mechanisms by which
BMI increases the risk of CVEs appear to be multifactorial
and may include, behavioral and social habits, alterations in
plasminogen activator inhibitor and fibrinolytic activity, an
increase in cardiac workload and stroke volume, and changes
in glucose and lipid metabolism.
Prior Studies
In a prior study of 755 patients with paroxysmal or per-
sistent AF,5 discontinuation of anticoagulant therapy with
warfarin was found to be safe except in patients who had a
prior stroke or who were >65 years old.
In another study, clinical outcomes after ablation of com-
plex fractionated atrial electrograms were assessed in 674 pa-
tients (40% with paroxysmal AF) >65 years old who had ≥
1 risk factor for stroke.12 Ablation was performed with a 4-
or 8-mm nonirrigated tip catheter. Sinus rhythm was main-
tained in 81% of the patients during a mean follow-up of 2
years. The mortality rate was higher in patients with recur-
rent AF than in patients who remained in sinus rhythm after
RFA. Age was an independent predictor of mortality. War-
farin was discontinued in 84% of the patients. There were a
total of 11 CVEs: 5 in patients who discontinued warfarin
and 6 in patients who continued warfarin. The 5-year stroke
rate was 3% versus 23% in patients who discontinued war-
farin and who remained on warfarin, respectively. However,
unlike in the present study, there was no control group in the
prior study. Because outcomes after RFA were assessed pri-
marily by clinical symptoms and asymptomatic recurrences
may not have been adequately captured, the CVE rate was
relatively low in this high-risk group of patients in the prior
study.
Limitations
A limitation of this study is that it is an observa-
tional study without prospective randomization of patients to
anticoagulant therapy after RFA. However, in the absence
of supportive data, discontinuation of warfarin after RFA in
high-risk patients would not be feasible.
A second limitation is that despite a large cohort of pa-
tients ≥65 years old who underwent RFA to eliminate AF,
the event rate was relatively low. Therefore, the study may
have been underpowered to identify all predictors of CVEs
after RFA.
A third limitation is that the mean duration of follow-up
was 3 years. Therefore, it may not be possible to predict
the long-term risk of CVEs in an aging population particu-
larly when age is a significant predictor of CVEs. However,
the data presented in this study were acquired over a 9-year
period. Another limitation may be that ablation techniques
and technologies have evolved during the study period. How-
ever, there were no temporal trends in the risk of CVEs in
this study.
To provide an estimate of the CVE rates in age-matched
human subjects with and without AF, comparisons were
made to hypothetical cohorts of patients based on the
Framingham study. However, these historical event rates may
not be representative of current event rates on contemporary
therapy.
Finally, the findings of this study apply to patients receiv-
ing anticoagulant therapy with warfarin. Whether the newer
oral anticoagulants will be more effective than warfarin in
preventing CVEs in the elderly remains to be determined.
However, because of a variety of factors, particularly cost,
warfarin is likely to remain widely used in a large proportion
of patients with AF.
Clinical Implications
The efficacy of RFA and the risk of periprocedural CVEs
appear to be similar in older and younger patients with AF,
therefore age should not be a criterion in estimating the risk
of stroke in patients contemplating an RFA procedure for AF.
Age >75 is the only predictor of CVEs after RFA of AF
in patients ≥65 years old, suggesting that the risk of CVEs in
older patients is because of mechanisms other than recurrent
AF or anticoagulation status. It remains to be determined
whether new oral antithrombin inhibitors or obliteration of
the left atrial appendage will lead to a decrease in CVEs in
elderly patients with AF.
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